Distribution of individual comorbidities among nonmyeloablative and myeloablative patients as assessed by the HCT-CI. Other comorbidities included rheumatologic, gastrointestinal, previous malignancy, and obesity. Of note, scores of 2 and 3 were assigned for moderate and severe pulmonary comorbidities, whereas scores of 1 and 3 were assigned for mild and moderate hepatic comorbidities.